Recombinant murine IFN alpha 5
≥ 5.0 mg/ml
<0.5 EU/mg as determined by the LAL method
≥98% monomer by analytical SEC
>95% by SDS Page
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
Next Day 2-8°C
Other Applications Reported In Literature ?
In Vitro Activity of TIF-3C5 - Inhibits IFNα-induced (IFNα-A, -1, -4, -5, -11 and 13) Stat1 phosphorylation in vitro, (TIF-1D6 does not block in vitro functional activity). Blocks IFNα (IFNα-A, -1, -4, -5, -11 and 13) induction of MHC-I expression (H2-Kb) using L929 or fibrosarcoma cell lines in a dose dependent manner. Neutralizes IFNα-induced antiviral activity in vitro following infection of L929 cells with VSV. Functional activity of both recombinant (IFNα-A, -1, -4, -5, -11 and 13) and natural IFNα can be blocked with no neutralization of IFNg or IFNb.
In vivo Activity of TIF-3C5- TIF-3C5 circulates with a half-life of 4 days- blockade of IFNa by TIF-3C5 increases the lethality of mice infected with West Nile Virus(WNV), similar to susceptibility of Irf7 -/- mice.
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Clone TIF-3C5 recognizes an epitope on mouse IFNα (subtypes IFN-αA, -1, -4, -5, -11, and -13) and does not bind murine IFNγ or IFNβ.
IFNα is expressed by hematopoietic cells, predominantly plasmacytoid dendritic cells (pDCs), following stimulation.
IFNα antibody, TIF-3C5, recognizes interferon (IFN)-α, a pleiotropic cytokine belonging to the type I IFN family of cytokines. IFNα is induced following recognition of microbial products via pattern-recognition receptors (PRRs). Hematopoietic cells, particularly plasmacytoid dendritic cells (pDCs), are the predominant source of IFNα following stimulation1,2. IFNα binds to the ubiquitously expressed common type I IFN receptor (IFNAR) that consists of the α-chain (IFNAR1) and the β-chain (IFNAR2), ultimately resulting in the transcription of various IFN-stimulated genes (ISGs) that contribute to antiviral immunity. ISGs directly promote antipathogenic activity by inhibiting viral entry, transcription, translation, and assembly in host cells. ISGs also synergize with other cytokines to activate innate effector cells, such as NK cells and dendritic cells (DCs), augment host adaptive immune responses, and enhance antigen presentation3. IFNα plays a role in the pathogenesis of autoimmune diseases, such as systemic lupus erythematosus (SLE)4. In addition, IFNα has multiple anti-tumor properties, including direct cytotoxicity of tumor cells and stimulating innate and adaptive immune cells, and IFNα is FDA-approved for the treatment of multiple cancers5.
References & Citations
1. Liu YJ., et al. (1999) Science. 284(5421):1835-7
2. Colonna M., et al. Nat Med (1999) 5(8):919-23
3. Trinchieri G. (2010) J Exp Med. 207(10):2053-2063
4. Kirou KA., et al. (2019) Annu Rev Pathol. 14:369-393
5. Huang TH., et al. (2019) PLoS One. 14(8):e0219829
Products are for research use only. Not for use in diagnostic or therapeutic procedures.